Equities analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to post ($0.39) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Tandem Diabetes Care’s earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.36). Tandem Diabetes Care posted earnings of ($3.09) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 87.4%. The business is expected to announce its next quarterly earnings results on Thursday, October 25th.
According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($3.17) per share for the current year, with EPS estimates ranging from ($3.59) to ($2.81). For the next year, analysts expect that the firm will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.25) to ($0.54). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Monday, July 30th. The medical device company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.82). The business had revenue of $34.10 million for the quarter, compared to the consensus estimate of $29.68 million. Tandem Diabetes Care’s revenue for the quarter was up 60.1% compared to the same quarter last year. During the same period last year, the business posted ($0.44) earnings per share.
Tandem Diabetes Care stock traded up $2.43 during trading hours on Wednesday, hitting $40.80. The company had a trading volume of 316,235 shares, compared to its average volume of 3,216,886. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of -3.04 and a beta of 0.02. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.02 and a quick ratio of 2.43. Tandem Diabetes Care has a 1 year low of $2.14 and a 1 year high of $40.04.
In other Tandem Diabetes Care news, Director Richard P. Valencia purchased 1,754 shares of Tandem Diabetes Care stock in a transaction dated Friday, August 3rd. The stock was acquired at an average price of $28.50 per share, for a total transaction of $49,989.00. Following the acquisition, the director now owns 1,754 shares in the company, valued at approximately $49,989. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 9.30% of the company’s stock.
Large investors have recently bought and sold shares of the company. Gabelli Funds LLC bought a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at about $102,000. Cetera Advisor Networks LLC bought a new position in shares of Tandem Diabetes Care during the 1st quarter worth approximately $117,000. Legal & General Group Plc bought a new position in shares of Tandem Diabetes Care during the 2nd quarter worth approximately $147,000. Element Capital Management LLC bought a new position in shares of Tandem Diabetes Care during the 1st quarter worth approximately $184,000. Finally, A.R.T. Advisors LLC raised its stake in shares of Tandem Diabetes Care by 284.4% during the 1st quarter. A.R.T. Advisors LLC now owns 38,518 shares of the medical device company’s stock worth $191,000 after acquiring an additional 28,499 shares in the last quarter. Institutional investors and hedge funds own 62.77% of the company’s stock.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Article: Dividend Stocks – Are They Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.